UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1787157 ( ...

Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Exhibit 99.1 ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates A ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC pati ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of a poster at the 2025 American Association for Cancer Research (AACR) Annual Meeting, highlighting preclinical data on ORIC-944, a potent, highly selective, orally bioavailable allosteric inhibitor of PRC2, which demonstrated synergistic ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that a preclinical abstract highlighting the potential of ORIC-944, a potent and selective allosteric inhibitor of PRC2 to treat prostate cancer, has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) Annual Me ...

Core Insights - ORIC Pharmaceuticals is focusing on registrational development plans for its lead programs, ORIC-944 and ORIC-114, targeting indications with strong clinical validation and high unmet needs [1][3] - The initiation of the first Phase 3 trial for ORIC-944 in metastatic castration-resistant prostate cancer (mCRPC) is expected in the first half of 2026, while ORIC-114's registrational trials for first-line non-small cell lung cancer (NSCLC) are anticipated to start in 2026 [1][3] - The company has extended its projected cash runway into 2027, allowing for accelerated corporate milestones [2][6] Registrational Development Plans - ORIC-944 is a potent allosteric inhibitor of PRC2, with a Phase 3 trial initiation planned for mCRPC in 1H 2026 [4] - ORIC-114 is an irreversible EGFR/HER2 inhibitor, with registrational trials focused on first-line NSCLC expected to begin in 2026 [5][7] Corporate Highlights - As of December 31, 2024, ORIC had cash, cash equivalents, and investments totaling $256 million, with an extended cash runway into 2027 based on a refined operating plan [6] - Favorable enrollment trends for both ORIC-944 and ORIC-114 are expected to lead to accelerated data reporting, including dose escalation data for ORIC-944 in 1H 2025 and comprehensive NSCLC data in 2H 2025 [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporatio ...

Financial Position - ORIC Pharmaceuticals reported cash and investments of $256 million as of December 31, 2024, expected to fund operations into late 2026[12]. - The company secured $125 million in financing during 2024, extending its cash runway into late 2026[2]. - The total stockholders' equity increased to $243.1 million as of December 31, 2024, up from $224.1 million in 2023[16]. Research and Development Expenses - Research and development (R&D) expenses for Q4 2024 were $32.0 million, up from $24.5 million in Q4 2023, representing a 29% increase[12]. - For the full year 2024, R&D expenses totaled $114.1 million, compared to $85.2 million in 2023, marking a 34% increase[12]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2024 were $7.6 million, compared to $6.9 million in Q4 2023, an increase of 10%[12]. Net Loss - The net loss for Q4 2024 was $36.3 million, compared to a net loss of $28.3 million in Q4 2023, reflecting a 28% increase in losses[18]. Clinical Programs and Trials - ORIC anticipates seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026[1]. - ORIC-944 is being evaluated in combination with apalutamide and darolutamide in ongoing Phase 1b trials for metastatic castration-resistant prostate cancer (mCRPC)[7]. - ORIC-114 is in clinical collaboration with Johnson & Johnson for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations[3].

Core Insights - ORIC Pharmaceuticals reported encouraging early safety and efficacy data for ORIC-944 in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC) [1] - The company entered a clinical trial collaboration with Johnson & Johnson to evaluate ORIC-114 in combination with amivantamab for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations [1][5] - ORIC anticipates seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in the second half of 2025 and early 2026 [1][2] - The company has a cash position of $256 million, expected to fund operations into late 2026 [1][11] Clinical Developments - ORIC-114 is being developed as a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor for NSCLC [3] - ORIC-944 is a potent and selective allosteric inhibitor of PRC2, currently in trials for prostate cancer [4] - The company has initiated multiple cohorts for ORIC-114 and ORIC-944, with ongoing trials showing promising results [2][5] - Preclinical data presented at major conferences indicate the potential best-in-class properties of both ORIC-114 and ORIC-944 [5][6] Financial Performance - For Q4 2024, ORIC reported R&D expenses of $32 million, up from $24.5 million in Q4 2023, reflecting increased external expenses and personnel costs [11] - General and administrative expenses for Q4 2024 were $7.6 million, compared to $6.9 million in Q4 2023 [11] - The total net loss for the year ended December 31, 2024, was $127.8 million, compared to $100.7 million for the previous year [16]